No Picture
News

Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ — Seal Rock Therapeutics, Inc., a clinical stage company developing […]